 |
97 Diseases |  |
247 Trials |
|
247 Trials |  |
14602 News |  |
| «12...2425262728293031323334...170171» |
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Pricing, HEOR, Cost effectiveness: 6/ Probabilistic sensitivity analyses showed: at willingness-to-pay threshold of $50k/ QALY, apixaban was preferred in 80% simulations. However, sensitivity analyses demonstrated: apixaban remained cost-effective at monthly cost<$530. Above this, rivaroxaban was cost-effective. (Twitter) - Dec 28, 2022
- ||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo
Clinical, Pricing, HEOR, Real-world evidence, Cost effectiveness, Real-world: 5/ However, the study results were vastly different with prices from GoodRx (real world prices). If decision makers were unwilling to spend more than $50k/ QALY, edoxaban was favored; using more flexible WTP threshold, rivaroxaban was cost-effective. (Twitter) - Dec 28, 2022
- ||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, apixaban / Generic mfg.
Clinical, HEOR, Drug cost, Cost effectiveness: 4/ In the base-case analysis, using the cost of drugs purchased at a federal facility such as the Veteran’s Administration, apixaban was favored as being more effective and less costly than either LMWH or edoxaban while indicating rivaroxaban was not cost-effective. (Twitter) - Dec 28, 2022
- |||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, apixaban / Generic mfg.
HEOR, Cost effectiveness: 1/ Happy to share: a cost effectiveness analysis of DOACs (apixaban, edoxaban, rivaroxaban) and LMWH for #thrombosis in cancer in @AnnalsofIM . A capstone project that developed into a manuscript with #MarkEckman at @uofcincy and completed at @UCD_Cancer https://t.co/xRmdLgiiNY (Twitter) - Dec 28, 2022
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Pricing, HEOR, Cost effectiveness: 6/ Probabilistic sensitivity analyses showed: at willingness-to-pay threshold of $50k/ QALY, apixaban was preferred in 80% simulations. However, sensitivity analyses demonstrated: apixaban remained cost-effective at monthly cost<$530. Above this, rivaroxaban was cost-effective. (Twitter) - Dec 28, 2022
- ||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo
Clinical, Pricing, HEOR, Real-world evidence, Cost effectiveness, Real-world: 4/ However, the study results were vastly different with prices from GoodRx (real world prices). If decision makers were unwilling to spend more than $50k/ QALY, edoxaban was favored; using more flexible WTP threshold, rivaroxaban was cost-effective. (Twitter) - Dec 28, 2022
- ||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, apixaban / Generic mfg.
Clinical, HEOR, Drug cost, Cost effectiveness: 3/ In the base-case analysis, using the cost of drugs purchased at a federal facility such as the Veteran’s Administration, apixaban was favored as being more effective and less costly than either LMWH or edoxaban while indicating rivaroxaban was not cost-effective. (Twitter) - Dec 28, 2022
- |||| rivaroxaban / Generic mfg., Savaysa (edoxaban) / Daiichi Sankyo, apixaban / Generic mfg.
HEOR, Cost effectiveness: 1/ Happy to share our latest work: a cost effectiveness analysis of DOACs (apixaban, edoxaban, rivaroxaban) and LMWH for #thrombosis in cancer (CAT) in @AnnalsofIM. A capstone project that developed into a manuscript with #MarkEckman at @uofcincy and completed at @UCD_Cancer (Twitter) - Dec 28, 2022
- | rivaroxaban / Generic mfg.
Journal: Characteristics and Effect of Rivaroxaban on Venous Thromboembolism in Korean Patients Compared to Western Population: A Subgroup Analysis from XALIA(-LEA) Study. (Pubmed Central) - Dec 28, 2022
Characteristic differences were found between Korean and Caucasian VTE patients. Despite these ethnic differences, the effectiveness and safety of rivaroxaban therapy in these patients were consistent.
- | rivaroxaban / Generic mfg.
Journal: Comparison of Commercial Low Molecular Weight Heparin and Homemade Anti-Xa Calibrators to a Commercial Specific Anti-Xa Calibrator for Plasma Rivaroxaban Quantification by Anti-Xa Oral Anticoagulant Plasma Concentration Chromogenic Assay. (Pubmed Central) - Dec 28, 2022
Despite these ethnic differences, the effectiveness and safety of rivaroxaban therapy in these patients were consistent. Our data showed that for estimating rivaroxaban concentrations, the LMWH calibrator could be used as an alternative calibrator in the anti-Xa assay.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: Resolving DOAC interference on antithrombin activity testing on a FXa based method by the use of activated carbon. (Pubmed Central) - Dec 28, 2022
Our data showed that for estimating rivaroxaban concentrations, the LMWH calibrator could be used as an alternative calibrator in the anti-Xa assay. AC effectively removes anti-FXa DOAC interference on FXa-based AT assays.
- ||| rivaroxaban / Generic mfg.
Trial completion: RITMUS-AF: Study Aims to Collect Information in Routine Clinical Practice in Italy About the Number of Patients Suffering From Irregularly Heart Beats Which Are Not Caused by a Heart Valve Problem (Non-valvular Atrial Fibrillation, NVAF) Who Stopped or Changed Rivaroxaban Treatment (clinicaltrials.gov) - Dec 28, 2022
P=N/A, N=737, Completed, Sponsor: Bayer
AC effectively removes anti-FXa DOAC interference on FXa-based AT assays. Active, not recruiting --> Completed
- || Savaysa (edoxaban) / Daiichi Sankyo
Clinical, Retrospective data, Review: Combination of antiplatelet and anticoagulant therapy, component network meta-analysis of randomized controlled trials. (Pubmed Central) - Dec 27, 2022
Vitamin K antagonist (VKA), rivaroxaban, or edoxaban did not reduced of MACE while it was associated with a significant increase of bleeding risk (RR 1.66; 3.66, and 5.47, respectively)...Long-term aspirin treatment as part of the anticoagulant and dual antiplatelet regimen provides no ischemic benefit but may increase bleeding risk. [https://www.crd.york.ac.uk/prospero/], identifier [259703].
- || rivaroxaban / Generic mfg.
Review, Journal: A comprehensive review on pathogenesis, associations, clinical findings, and treatment of livedoid vasculopathy. (Pubmed Central) - Dec 27, 2022
Among them, pain management, wound care, control of cardiovascular risk factors, and both antiplatelets and anticoagulants, mostly rivaroxaban, are the main therapies used. These different therapies as well as their degree of evidence are reviewed.
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal, HEOR, Cost-effectiveness, Cost effectiveness: Anticoagulant Therapy for Cancer-Associated Thrombosis : A Cost-Effectiveness Analysis. (Pubmed Central) - Dec 27, 2022
Direct oral anticoagulants (DOACs) offer an alternative to low-molecular-weight heparin (LMWH) and warfarin for treating cancer-associated thrombosis (CAT)...Strategies of 1) enoxaparin, 2) apixaban, 3) edoxaban, and 4) rivaroxaban for treatment of CAT...These are important considerations for treating physicians and health policymakers. None.
- | AndexXa (coagulation factor Xa (recombinant), inactivated -zhzo) / Daiichi Sankyo, AstraZeneca
Journal: Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. (Pubmed Central) - Dec 26, 2022
There were no statistically significant differences between the groups for secondary outcomes, including 28-day mortality (40.4% vs 39.1%, p = 0.92) and thrombotic complications within 28 days of reversal (17.0% vs 21.7%, p = 0.63). In patients who experienced an ICH while taking apixaban or rivaroxaban, 4F-PCC and AA were found to have similar rates of excellent or good hemostatic efficacy.
- || rivaroxaban / Generic mfg., aspirin / Generic mfg., acenocoumarol / Generic mfg.
Clinical, Journal: Rivaroxaban plus aspirin versus acenocoumarol to manage recurrent venous thromboembolic events despite systemic anticoagulation with rivaroxaban. (Pubmed Central) - Dec 25, 2022
In this pilot study, there were no significant differences in any outcome assessed; however, recurrent thromboembolic events and minor bleeding events occurred numerically less frequently in the rivaroxaban plus aspirin group. These data suggest the need to carry out more extensive randomized studies with sufficient statistical power to clarify these results.
- | rivaroxaban / Generic mfg.
Journal: Design and Optimization of Rivaroxaban-Cyclodextrin-Polymer Triple Complex Formulation with Improved Solubility. (Pubmed Central) - Dec 24, 2022
The R-C-P complex formulation secured high RIV solubility and 100% release regardless of pH. The results imply that high-dose RIV can be administered regardless of the meal, reducing the risk of changing the drug effect due to the patient's administration mistake.
- | Journal: Comparison of the effectiveness and safety of direct oral anticoagulants: nationwide propensity score-weighted study. (Pubmed Central) - Dec 24, 2022
In the pivotal randomized controlled trials (RCTs) for patients with atrial fibrillation, direct oral anticoagulants (DOACs) had similar or even superior efficacy and safety compared to warfarin...In this nationwide cohort study, rates of any stroke or systemic embolism (stroke/SE) and major bleeding were compared between new users of apixaban, dabigatran, and rivaroxaban with atrial fibrillation from 2014-2019...In conclusion, while stroke/SE rates were similar between DOACs, rivaroxaban was associated with higher rates of major bleeding compared to other DOACs and lower rates of myocardial infarction compared to dabigatran. These results may help guide oral anticoagulant selection, especially in patients at high risk of bleeding or myocardial infarction.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
Journal: Hemostatic Efficacy and Safety of 4-Factor Prothrombin Complex Concentrate in Doac-Associated Intracranial Hemorrhage. (Pubmed Central) - Dec 24, 2022
76 patients on apixaban or rivaroxaban were included...Favorable discharge disposition and lower in-hospital mortality was more likely in patients who achieved excellent hemostasis. 4F-PCC is safe and effective for FXa inhibitor associated ICH.
- || Savaysa (edoxaban) / Daiichi Sankyo
Retrospective data, Review, Journal: Clinical and Safety Outcomes Associated with Extended Treatment of Venous Thromboembolism: A Network Meta-Analysis. (Pubmed Central) - Dec 23, 2022
There existed no statistically significant differences in recurrence between NOACs and standard-intensity warfarin, and NOACs were associated with a lower risk of bleeding events. Edoxaban effectively prevented VTE recurrence and major bleeding, and apixaban was the best anticoagulant for controlling bleeding events.
- ||||| rivaroxaban / Generic mfg.
Enrollment change: BRAIN-AF: Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF (clinicaltrials.gov) - Dec 22, 2022
P3, N=1424, Recruiting, Sponsor: Montreal Heart Institute
Edoxaban effectively prevented VTE recurrence and major bleeding, and apixaban was the best anticoagulant for controlling bleeding events. N=2180 --> 1424
- | rivaroxaban / Generic mfg.
Enrollment open, Trial initiation date: Xarelto for Thromboprophylaxis After Total Hip and Total Knee Arthroplasty (clinicaltrials.gov) - Dec 21, 2022
P=N/A, N=178, Recruiting, Sponsor: Chiayi Christian Hospital
N=2180 --> 1424 Not yet recruiting --> Recruiting | Initiation date: Jul 2022 --> Dec 2022
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Journal: Rationale and Design of Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation (REWRAPS). (Pubmed Central) - Dec 20, 2022
P4
The primary composite endpoint was net adverse clinical events (NACE), defined as a combination of all-cause death and major bleeding. Completion of REWRAPS will provide, for the first time, evidence as to whether rivaroxaban is superior or non-inferior to warfarin with regard to the primary efficacy (MACCE), safety (major bleeding), or combined (all-cause death, major bleeding) endpoints in real-world patients with AF, coronary stenting, and underlying CKD an average of 5 years after PCI.
- | rivaroxaban / Generic mfg., rifampicin / Generic mfg.
New trial, Combination therapy: Dose Optimization of Rivaroxaban Combined With Rifampicin (clinicaltrials.gov) - Dec 20, 2022
P=N/A, N=80, Recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- || warfarin / Generic mfg.
Retrospective data, Review: The Risk of Postpolypectomy Bleeding in Patients Receiving Direct Oral Anticoagulants compared to Warfarin or Nonanticoagulation: A Systematic Review with Meta-Analysis. (Pubmed Central) - Dec 20, 2022
DOACs can significantly raise the risk of PPB, even with 24-hour withdrawal before polypectomy. In addition, a lower risk of PPB was detected for dabigatran than for warfarin.
- | rivaroxaban / Generic mfg., warfarin / Generic mfg.
Phase classification, Trial completion date: Rivaroxaban Estimation With Warfarin in Atrial Fibrillation Patients With Coronary Stent Implantation Study (REWRAPS) (clinicaltrials.gov) - Dec 20, 2022
P4, N=500, Completed, Sponsor: Fujita Health University
In addition, a lower risk of PPB was detected for dabigatran than for warfarin. Phase classification: P=N/A --> P4 | Trial completion date: Dec 2021 --> Dec 2022
- |||| rivaroxaban / Generic mfg., enoxaparin sodium / Generic mfg., apixaban / Generic mfg.
Clinical: Exactly. RECORD and ADVANCE trials support NOAC for DVT prophylaxis post hip and knee replacement. Enoxaparin 40mg $AU3.5/day, apixaban 2.5mg BD $AU2.7/day, rivaroxaban 10mg $AU2/day…seems like low hanging fruit for medical inpatients and probably surgical too… (Twitter) - Dec 19, 2022
- | Savaysa (edoxaban) / Daiichi Sankyo
Journal: PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study. (Pubmed Central) - Dec 18, 2022
The study demonstrated that the prevalence of inappropriate direct oral anticoagulant dosing according to the European Heart Rhythm Association recommendations was 24.9% in patients with atrial fibrillation. Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants.
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Clinical: Hey #vasctwitter @farkomd @mattsmeds @DrAndrewChoong @ozvascdoc @ManarKhashram @XavierBerardMD @FlindersVasc @monteromiguel @b_modarai @limbsalvagedr @heatherlgornik @FutureVascSurgn Anyone using apixaban/rivaroxaban low dose in place of LMWH for DVT prophylaxis in surgical pts? (Twitter) - Dec 18, 2022
- | rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., warfarin / Generic mfg.
Journal: Effectiveness and Safety of DOACs in Atrial Fibrillation Patients Undergoing Catheter Ablation: Results from the China Atrial Fibrillation (China-AF) Registry. (Pubmed Central) - Dec 17, 2022
Several demographic and clinical factors were associated with the inappropriate prescription of direct oral anticoagulants. In this study, the incidence of TE and MB were both comparable in standard- or low-dose DOACs versus warfarin and between the two DOACs, whereas the risk of non-MB was higher in rivaroxaban than in warfarin and in R than in D.
- | Avastin (bevacizumab) / Roche, Sutent (sunitinib) / Pfizer, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
Retrospective data, Journal: Safety of direct oral anticoagulants in patients with advanced solid tumors receiving anti-VEGF agents: a retrospective study. (Pubmed Central) - Dec 17, 2022
The use of direct oral anticoagulants (DOACs) apixaban and rivaroxaban is increasing in cancer patients, but limited data are available for patients receiving anti-VEGF agents...Grade ≥ 3 TE occurred in 8 patients (9%): 7 patients receiving bevacizumab (including one grade 5 pulmonary embolism), and one patient receiving sunitinib (grade 3 pulmonary embolism)...CONCLUSIONS AND RELEVANCE: In our experience, the use of DOAC was safe in selected patients treated with KI, but unclear with bevacizumab. More data are needed to endorse guidelines in this specific group of patients.
- | rivaroxaban / Generic mfg.
Journal: Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study. (Pubmed Central) - Dec 16, 2022
One patient had recurrent VTE after dose reduction, and seven had non-fatal major bleeding. Therefore, rivaroxaban had a sufficient clot-regression effect against CAT with caution of bleeding complication.
- | rivaroxaban / Generic mfg.
Journal: Eligibility and Implementation of Rivaroxaban for Secondary Prevention of Atherothrombosis in Clinical Practice-Insights From the CANHEART Study. (Pubmed Central) - Dec 16, 2022
Eligible individuals with 2 comorbidities represent a high-risk subgroup that may derive the greatest benefit-to-risk ratio. Selection of patients with high-risk predisposing factors appears appropriate in routine practice.
- || rivaroxaban / Generic mfg.
Clinical, Journal: Rivaroxaban treatment for six weeks versus three months in patients with symptomatic isolated distal deep vein thrombosis: randomised controlled trial. (Pubmed Central) - Dec 16, 2022
P3
Selection of patients with high-risk predisposing factors appears appropriate in routine practice. Rivaroxaban administered for six additional weeks in patients with isolated distal DVT who had an uneventful six week treatment course reduces the risk of recurrent venous thromboembolism, mainly recurrent isolated distal DVT, over a two year follow-up without increasing the risk of haemorrhage.
- Brukinsa (zanubrutinib) / BeiGene
Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial () - Dec 16, 2022 - Abstract #TCTASTCTCIBMTR2023TCT_ASTCT_CIBMTR_751;
P2
None of the pts required dose reduction. Conclusions : In this final analysis with over 2 years of median follow-up, zanubrutinib continues to demonstrate durable disease control and was generally well tolerated, with no new safety signals observed.
- ||| rivaroxaban / Generic mfg.
The doses of Xarelto were correct? Some particular etiology? No antiphospholipid syndrome ? (Twitter) - Dec 16, 2022
- |||| rivaroxaban / Generic mfg.
Clinical: @AlexSpyropoul Are the DOACs efficacy affected by weight for treatment of VTE? Specifically, the morbidly obese patients. My Heme colleague has prescribed Xarelto 25 mg for 300 lb. patients once in a while. Ευχαριστώ. Great talk at the Scholarship Awards last Friday! (Twitter) - Dec 15, 2022
- || rivaroxaban / Generic mfg.
Trial completion date, Trial primary completion date, Surgery, Bariatric surgery: BARIVA: Rivaroxaban as Thrombosis Prophylaxis in Bariatric Surgery (clinicaltrials.gov) - Dec 15, 2022
P2, N=260, Active, not recruiting, Sponsor: University Hospital Inselspital, Berne
Conclusions : In this final analysis with over 2 years of median follow-up, zanubrutinib continues to demonstrate durable disease control and was generally well tolerated, with no new safety signals observed. Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023
- || Savaysa (edoxaban) / Daiichi Sankyo, Bevyxxa (betrixaban) / AstraZeneca
Enrollment change: CORRAL-AF: Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF (clinicaltrials.gov) - Dec 15, 2022
P=N/A, N=3181, Not yet recruiting, Sponsor: Brian O'Neill MD
Trial completion date: Dec 2022 --> Dec 2023 | Trial primary completion date: Dec 2022 --> Dec 2023 N=15 --> 3181
- rivaroxaban / Generic mfg.
Pulmonary embolism: epidemiological, diagnostic, therapeutic and scalable aspects at the cardiology service of the Idrissa Pouye hospital in Dakar about 89 cases (Display area) - Dec 14, 2022 - Abstract #CPLF2023CPLF_733;
Rivaroxaban was used in 15 patients (16.9%)...It is a multifactorial pathology whose management must include the research and treatment of the etiological factor. In our context, surgical factors are still frequent hence the need for prevention.
- |||| rivaroxaban / Generic mfg., dabigatran etexilate / Generic mfg., apixaban / Generic mfg.
Clinical: Overcoming commercial bias:Dabigatran was 1st DOAC to be introduced into clinical practice in Israel followed by rivaroxaban, and apixaban. Therefore, treatment assignment was identified by index prescription only after Jan 2014, when the use of all three drugs was available. (Twitter) - Dec 14, 2022
- || rivaroxaban / Generic mfg.
Listen, as a CARDS PharmD, I'm biased. But those are literally dancing Xarelto tablets. (Twitter) - Dec 14, 2022
- | rivaroxaban / Generic mfg.
Journal: Efficacy and Safety Assessment of Rivaroxaban for the Treatment of Cerebral Venous Sinus Thrombosis in a Chinese Population. (Pubmed Central) - Dec 13, 2022
Patients with cerebral edema, intracerebral hemorrhage, and mild/moderate disability (admission mRS score [2-3]) treated with rivaroxaban recovered faster than those with warfarin (log-rank P < .05). Patients with cerebral edema, intracerebral hemorrhage, and mild/moderate disability treated with rivaroxaban had a shorter recovery time than those treated with warfarin within 1 month from admission, indicating that rivaroxaban a promising convenient therapy for CVST, helping them speedily restore social functions.
- | rivaroxaban / Generic mfg.
Journal: ANMCO Position paper: Evidence and practical indications for the use of low-dose rivaroxaban in stable coronary artery disease and peripheral artery disease (Pubmed Central) - Dec 13, 2022
However, in Italy, the national health system reimbursement is provided only for patients with PAD. In patients treated with rivaroxaban 2.5 mg, assessment and monitoring of bleeding risk is crucial to achieve the maximum clinical benefit.
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Clinical: This is so frustrating!! Apixaban and rivaroxaban are NOT interchangeable in every clinical situation. Patients and clinicians need equal access to both medications to ensure safe and effective #cvCoag care. (Twitter) - Dec 13, 2022
- ||| rivaroxaban / Generic mfg., apixaban / Generic mfg.
Clinical: Did you take into account that patients on rivaroxaban would, on average, have been longer on treatment than those on apixaban as the latter came later into the market? Was this included in the matching? (Twitter) - Dec 13, 2022
- || rivaroxaban / Generic mfg., warfarin / Generic mfg., apixaban / Generic mfg.
PK/PD data, Journal: Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients. (Pubmed Central) - Dec 13, 2022
In exploratory analyses with other genetic models, the ABCB1 (rs4148732) GG genotype tended to be associated with the risk of bleeding from rivaroxaban [HR: 1.391 (95%CI: 1.019-1.900); p = 0.038] but not from apixaban (p = 0.487). Eight functional PK-related genetic variants were not significantly associated with bleeding from either rivaroxaban or apixaban in more than 2,000 AF self-identified white outpatients.
- || VMX-C001 / VarmX
Enrollment change, Combination therapy: Study of Intravenous VMX-C001 in Healthy Subjects and in Combination With Selected Direct Oral Anticoagulants in Healthy Older Subjects (clinicaltrials.gov) - Dec 13, 2022
P1, N=128, Recruiting, Sponsor: VarmX B.V.
Eight functional PK-related genetic variants were not significantly associated with bleeding from either rivaroxaban or apixaban in more than 2,000 AF self-identified white outpatients. N=88 --> 128
- | rivaroxaban / Generic mfg.
Journal, Real-world evidence: Real world experience of efficacy and safety of rivaroxaban in paediatric venous thromboembolism. (Pubmed Central) - Dec 12, 2022
Our real-world experience confirmed that rivaroxaban was well tolerated, effective and safe. Further real-world data and observational studies are essential to investigate the use of rivaroxaban among different risk groups.